North East and North Cumbria
ICS Formulary
 
back
2 Cardiovascular system
02-02-03 Potassium-sparing diuretics and aldosterone antagonists

Amiloride Hydrochloride
First Choice

Green View adult BNF  View SPC online  View childrens BNF
Finerenone Kerendia®
Formulary
  • Approved as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults - in line with NICE TA877:
    • add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
      • angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
      • sodium–glucose cotransporter‑2 (SGLT2) inhibitors and
    • the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more.
Link  NENC - Finerenone for treating chronic kidney disease in people with type 2 diabetes
Link  NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes

Green plus View adult BNF  View SPC online  View childrens BNF